Kawada, T., Katayama, S., Yanagisawa, T., Mori, K., Fukuokaya, W., Komura, K., Tsujino, T., Maenosono, R., Takahara, K., Nukaya, T., Inoki, L., Toyoda, S., Hashimoto, T., Hirasawa, Y., Edamura, K., Kobayashi, T., Bekku, K., Nishimura, S., Iwata, T., Sadahira, T., Tominaga, Y., Yamanoi, T., Yoshinaga, K., Tsuboi, K., Kobayashi, Y., Takamoto, A., Kurose, K., Kimura, T., Azuma, H., Shiroki, R., Fujita, K., Ohno, Y., Araki, M. (2025). Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy. Scientific Reports. https://doi.org/10.1038/s41598-025-08767-9